Physician profile
James W Ortmeyer
NPI 1598761470
$1,238.24
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $459 · 2021: $80.82 · 2022: $235.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $324.52 | 2019-2021 | |
| Inari Medical, INC. | $208.85 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.00 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $105.39 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $85.37 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $50.69 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $42.33 | 2019 | |
| Novartis Pharmaceuticals Corporation | $38.96 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $38.66 | 2019 | |
| Merck Sharp & Dohme LLC | $30.33 | 2019 | |
| Abbvie INC. | $26.61 | 2022 | |
| Circassia INC. | $24.86 | 2019 | |
| Philips North America LLC | $19.24 | 2019 | |
| Mallinckrodt Hospital Products INC. | $19.02 | 2020 | |
| Shire North American Group INC | $16.27 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $12.14 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ortmeyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.